SKYE Earnings

SKYE reported its earnings on 2026-03-23, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.29 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following SKYE's earnings announcement on 2026-03-23, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, SKYE's stock price tends to shift by an average of 14.45% in the 10 days leading up to earnings and -4.1% in the 10 days following, providing insight into potential market.

For , analysts estimate SKYE's annual revenue to reach undefined, while the EPS is projected at -0.31. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SKYE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SKYE's stock price typically moves by 14.45% in the 10 days before its earnings and -4.1% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.31 and revenue of undefined.

The earnings call reveals mixed signals. Financial performance shows increased R&D expenses and a larger net loss, but cash reserves are solid. Product development is promising, with positive feedback on Nimacimab and its potential in obesity treatment. However, uncertainties remain, particularly regarding weight regain issues and the need for higher dosing. The Q&A session highlighted optimism about future trials but also exposed gaps in understanding current data. Overall, the financial health and product prospects balance out, leading to a neutral sentiment.